| Dr Steven Jon Schwartz, MD | |
|
Johns Hopkins University, 600 N. Wolfe Street Meyer 297a, Baltimore, MD 21287-0001 | |
| (410) 955-9080 | |
| (410) 955-8978 |
| Full Name | Dr Steven Jon Schwartz |
|---|---|
| Gender | Male |
| Speciality | Critical Care (intensivists) |
| Experience | 35 Years |
| Location | Johns Hopkins University, Baltimore, Maryland |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1194714329 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RC0200X | Internal Medicine - Critical Care Medicine | D0053850 (Maryland) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| West Florida Hospital | Pensacola, FL | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Intensive Care Consortium Inc | 0244269413 | 370 |
News Archive
Treatment with two medications that target the most common genetic cause of cystic fibrosis improves lung function and lowers the rate of pulmonary exacerbations, according to the results from a Phase III international clinical trial published online in the New England Journal of Medicine on May 17, 2015.
In the last several years, targeted therapies - drugs that directly impact specific genes and proteins involved in the progression of cancer - have been approved for a wide variety of cancers, including melanoma, the deadliest form of skin cancer. Now, researchers at The Wistar Institute have discovered one way in which melanoma becomes resistant to a particular form of targeted therapy, and understanding this phenomenon may lead to a new melanoma target or prompt new designs of these treatments.
A study by Canadian researchers Eva Lonn, M.D., of the Population Health Research Institute and McMaster University, Hamilton Health Sciences Corporation, Hamilton, Ontario, Canada, and colleagues, has found from examining experimental and epidemiological data, that patients who took vitamin E supplements for 7 years did not significantly reduce their risk of cancer or cardiovascular events and some in fact had an increased risk of heart failure.
A study of the human genome led by Cedars-Sinai researchers has now identified genes linked to ulcerative colitis, offering clues as to what causes the condition and potential avenues for new therapies to treat the disease.
› Verified 5 days ago
| Entity Name | Intensive Care Consortium Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1629019062 PECOS PAC ID: 0244269413 Enrollment ID: O20050808000883 |
News Archive
Treatment with two medications that target the most common genetic cause of cystic fibrosis improves lung function and lowers the rate of pulmonary exacerbations, according to the results from a Phase III international clinical trial published online in the New England Journal of Medicine on May 17, 2015.
In the last several years, targeted therapies - drugs that directly impact specific genes and proteins involved in the progression of cancer - have been approved for a wide variety of cancers, including melanoma, the deadliest form of skin cancer. Now, researchers at The Wistar Institute have discovered one way in which melanoma becomes resistant to a particular form of targeted therapy, and understanding this phenomenon may lead to a new melanoma target or prompt new designs of these treatments.
A study by Canadian researchers Eva Lonn, M.D., of the Population Health Research Institute and McMaster University, Hamilton Health Sciences Corporation, Hamilton, Ontario, Canada, and colleagues, has found from examining experimental and epidemiological data, that patients who took vitamin E supplements for 7 years did not significantly reduce their risk of cancer or cardiovascular events and some in fact had an increased risk of heart failure.
A study of the human genome led by Cedars-Sinai researchers has now identified genes linked to ulcerative colitis, offering clues as to what causes the condition and potential avenues for new therapies to treat the disease.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Steven Jon Schwartz, MD 17 Halbright Ct, Lutherville, MD 21093-7003 Ph: (410) 303-4999 | Dr Steven Jon Schwartz, MD Johns Hopkins University, 600 N. Wolfe Street Meyer 297a, Baltimore, MD 21287-0001 Ph: (410) 955-9080 |
News Archive
Treatment with two medications that target the most common genetic cause of cystic fibrosis improves lung function and lowers the rate of pulmonary exacerbations, according to the results from a Phase III international clinical trial published online in the New England Journal of Medicine on May 17, 2015.
In the last several years, targeted therapies - drugs that directly impact specific genes and proteins involved in the progression of cancer - have been approved for a wide variety of cancers, including melanoma, the deadliest form of skin cancer. Now, researchers at The Wistar Institute have discovered one way in which melanoma becomes resistant to a particular form of targeted therapy, and understanding this phenomenon may lead to a new melanoma target or prompt new designs of these treatments.
A study by Canadian researchers Eva Lonn, M.D., of the Population Health Research Institute and McMaster University, Hamilton Health Sciences Corporation, Hamilton, Ontario, Canada, and colleagues, has found from examining experimental and epidemiological data, that patients who took vitamin E supplements for 7 years did not significantly reduce their risk of cancer or cardiovascular events and some in fact had an increased risk of heart failure.
A study of the human genome led by Cedars-Sinai researchers has now identified genes linked to ulcerative colitis, offering clues as to what causes the condition and potential avenues for new therapies to treat the disease.
› Verified 5 days ago
Dr. Leonard Anang Sowah, M.D. Critical Care Medicine Medicare: Medicare Enrolled Practice Location: 22 S Greene St, Baltimore, MD 21201 Phone: 410-706-4619 Fax: 410-706-2062 | |
Dr. Bhavandeep Singh Bajaj, M.D. Critical Care Medicine Medicare: Accepting Medicare Assignments Practice Location: 3345 Wilkens Avenue, Suite L10, Baltimore, MD 21229 Phone: 410-644-4444 Fax: 410-644-4484 | |
Dr. Yonas Sisay, M.D. Critical Care Medicine Medicare: Not Enrolled in Medicare Practice Location: 822 Guilford Ave, #100, Baltimore, MD 21202 Phone: 410-385-9672 | |
Dr. Stephen John Witanowski, MD Critical Care Medicine Medicare: Medicare Enrolled Practice Location: 2700 Quarry Lake Dr, Suite 280, Baltimore, MD 21209 Phone: 410-469-5544 Fax: 410-585-2867 | |
Dr. Susrutha Kotwal, MD Critical Care Medicine Medicare: Accepting Medicare Assignments Practice Location: 4940 Eastern Ave, Mfl Bldg, West Tower, 6th Floor, Baltimore, MD 21224 Phone: 410-550-5018 | |
Dr. Mitesh G Trambadia, M.D. Critical Care Medicine Medicare: Medicare Enrolled Practice Location: 6701 N Charles St Ste 5218, Baltimore, MD 21204 Phone: 443-849-3786 | |
Ronak K Patel, M.D. Critical Care Medicine Medicare: Accepting Medicare Assignments Practice Location: 201 E University Pkwy, Baltimore, MD 21218 Phone: 410-554-2000 |